Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Frontline Maintenance With Niraparib Plus Bevacizumab Is Active in Advanced Ovarian Cancer

March 16th 2025

Frontline maintenance with niraparib and bevacizumab showed efficacy and safety profiles that are in line with similar regimens in advanced ovarian cancer.

Luveltamab Tazevibulin Produces Responses in Platinum-Resistant Ovarian Cancer With Low/Medium FRα Expression

March 16th 2025

Luveltamab tazevibulin was active and safe in patients with platinum-resistant ovarian cancer and a FRα expression of at least 25%.

Updated MIRASOL Data Support Mirvetuximab Soravtansine as SOC for FRα+ Platinum-Resistant Ovarian Cancer

March 16th 2025

Mirvetuximab soravtansine continued to showcase superior OS, PFS, ORR, & DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.

Cyclin E1 Positivity Predicts Response to Azenosertib in Platinum-Resistant Ovarian Cancer

March 16th 2025

Patients with cyclin E1–positive platinum-resistant ovarian cancer experienced a greater response to azenosertib vs the overall DENALI population.

Pembrolizumab Plus Olaparib Improves PFS in BRCA Wild-Type Ovarian Cancer

March 16th 2025

The KEYLYNK-001 trial found improved PFS among patients with advanced ovarian cancer given pembrolizumab/olaparib.

Afuresertib Plus Paclitaxel Does Not Elicit Substantial Clinical Benefit in Platinum-Resistant Ovarian Cancer

March 15th 2025

Afuresertib combined with paclitaxel did not elicit PFS or OS benefits vs paclitaxel alone in patients with unselected platinum-resistant ovarian cancer.

Dr Moore on Novel ADCs Under Development in FRα+ Ovarian Cancer

March 12th 2025

Kathleen N. Moore, MD, MS, discusses novel antibody-drug conjugates currently in development for patients with FRα-expressing ovarian cancer.

Dr Hinchcliff on the Evolving Role of ADCs in Ovarian Cancer

March 6th 2025

Emily M. Hinchcliff, MD, MPH, discusses the growing role of ADCs like mirvetuximab soravtansine for the treatment of patients with ovarian cancer.

Data Compilation Highlights Potential of SON-1010 to Enhance Therapeutic Efficacy in Solid Tumors

March 5th 2025

SON-1010 is being investigated for its potential to improve outcomes in solid tumors.

Five Under 5: Top Oncology Videos for the Week of 2/23

March 2nd 2025

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

Dr Lheureux on Advancements in Targeted Treatment Delivery for Ovarian Cancer

February 25th 2025

Stéphanie Lheureux, MD, PhD, discusses technological advancements in ovarian cancer that could optimize treatment delivery, timing, and sequencing.

Avutometinib/Defactinib Combo Could Fill Sizeable Unmet Need in LGSOC

February 17th 2025

Ritu Salani, MD, MBA, details the significance of trials examining avutometinib plus defactinib and enthusiasm for ADCs in ovarian cancer.

FDA Grants Fast Track Designation to CUSP06 for Platinum-Resistant Ovarian Cancer

February 12th 2025

CUSP06 received fast track designation from the FDA for patients with platinum-resistant ovarian cancer.

Precise Targets and Drug Sequencing Potential Characterize the State of ADCs in Ovarian Cancer

February 11th 2025

Kathleen N. Moore, MD, MS, discusses ongoing trials of novel ADCs in ovarian cancer and the potential relevance of biomarker expression for these agents.

Dr Moore on the 2024 FDA Approval of Mirvetuximab Soravtansine in Ovarian Cancer

February 10th 2025

Kathleen N. Moore, MD, MS, details the March 2024 approval of mirvetuximab soravtansine for the treatment of FRα–positive ovarian cancer.

Ongoing Research to Watch in Ovarian Cancer

February 6th 2025

Floortje J. Backes, MD, discusses ongoing research to watch in ovarian cancer.

Additional Potential Roles for Mirvetuximab Soravtansine and Other ADCs in Ovarian Cancer

February 6th 2025

Floortje J. Backes, MD, discusses other potential roles for mirvetuximab soravtansine and other antibody-drug conjugates in ovarian cancer.

PICCOLO Data for Mirvetuximab Soravtansine in FRα+, Platinum-Sensitive Ovarian Cancer

February 6th 2025

Floortje J. Backes, MD, discusses data for mirvetuximab soravtansine in FRα-positive, platinum-sensitive ovarian cancer

Testing for FRα in Ovarian Cancer

February 6th 2025

Floortje J. Backes, MD, discusses how to approach FRα testing in ovarian cancer.

How Mirvetuximab Soravtansine Has Impacted Clinical Management of Ovarian Cancer

February 6th 2025

Floortje J Backes, MD, discusses how mirvetuximab soravtansine has affected the management of platinum-resistant ovarian cancer.